Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance) Meeting Abstract
| Authors: | Dickler, M. N.; Barry, W. T.; Cirrincione, C. T.; Ellis, M. J.; Moynahan, M. E.; Innocenti, F.; Hurria, A.; Rugo, H. S.; Lake, D.; Hahn, O. M.; Schneider, B. P.; Tripathy, D.; Winer, E. P.; Hudis, C. A. |
| Abstract Title: | Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance) |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036901051 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2015.33.15_suppl.501 |
| Notes: | Meeting Abstract: 501 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
